Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 16:50
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
A hiker in Alaska was in distress. A webcam used to livestream bears led to his rescue
Post Malone and Joe Rogan call the NPC TikTok trend 'crazy' and 'strange'
Travis Barker's daughter Alabama calls for body positivity after troll calls her 'fat as f***'
Capcom wants to know if more Resident Evil remakes are wanted!
Andrew Tate believes woman's happiness lies in taking care of her man 'no matter the circumstances', Internet says 'what a flawed idiotic logic'
Eastern Libya authorities say 2,000 dead in flood, thousands missing
US SEC sues Coinbase, one day after suing Binance
Intel: Our 3D V-Cache Tech Will Take a Different Approach Than AMD